» Articles » PMID: 11985489

Mechanisms of Fungal Resistance: an Overview

Overview
Journal Drugs
Specialty Pharmacology
Date 2002 May 3
PMID 11985489
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The increased use of antifungal agents in recent years has resulted in the development of resistance to these drugs. The significant clinical implication of resistance has led to heightened interest in the study of antifungal resistance from different angles. In this article we discuss antifungal susceptibility testing, the mode of action of antifungals and mechanisms of resistance. Antifungals are grouped into five groups on the basis of their site of action: azoles, which inhibit the synthesis of ergosterol (the main fungal sterol); polyenes, which bind to fungal membrane sterol, resulting in the formation of aqueous pores through which essential cytoplasmic materials leak out; allylamines, which block ergosterol biosynthesis, leading to accumulation of squalene (which is toxic to the cells); candins (inhibitors of the fungal cell wall), which function by inhibiting the synthesis of beta 1,3-glucan (the major structural polymer of the cell wall); and flucytosine, which inhibits macromolecular synthesis. Different mechanisms contribute to the resistance of antifungal agents. These mechanisms include modification of ERG11 gene at the molecular level (gene mutation, conversion and overexpression), over expression of specific drug efflux pumps, alteration in sterol biosynthesis, and reduction in the intracellular concentration of target enzymes. Approaches to prevent and control the emergence of antifungal resistance include prudent use of antifungals, treatment with the appropriate antifungal and conducting surveillance studies to determine the frequency of resistance.

Citing Articles

Essential oils as promising treatments for treating infections: research progress, mechanisms, and clinical applications.

Hou G, Huang T Front Pharmacol. 2024; 15:1400105.

PMID: 38831882 PMC: 11145275. DOI: 10.3389/fphar.2024.1400105.


Isolation of coumarins with anti-Trichophyton rubrum activity from Heracleum vicinum Boiss.

Wu H, Liu M, Liu S, Yu H, Chen H Braz J Microbiol. 2023; 54(2):1093-1102.

PMID: 37145298 PMC: 10235337. DOI: 10.1007/s42770-023-00988-2.


Antifungal activity screening of fractions from Annona cherimola Mill. leaf extract against Fusarium oxysporum.

Mendez-Chavez M, Ledesma-Escobar C, Hidalgo-Morales M, Rodriguez-Jimenes G, Robles-Olvera V Arch Microbiol. 2022; 204(6):330.

PMID: 35579717 DOI: 10.1007/s00203-022-02944-4.


Assessing the Fungal Simultaneous Removal Efficiency of Carbamazepine, Diclofenac and Ibuprofen in Aquatic Environment.

Kasonga T, Coetzee M, Kamika I, Momba M Front Microbiol. 2021; 12:755972.

PMID: 34966363 PMC: 8710540. DOI: 10.3389/fmicb.2021.755972.


Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens.

Rosam K, Monk B, Lackner M J Fungi (Basel). 2020; 7(1).

PMID: 33374996 PMC: 7822023. DOI: 10.3390/jof7010001.


References
1.
Sheehan D, Hitchcock C, Sibley C . Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999; 12(1):40-79. PMC: 88906. DOI: 10.1128/CMR.12.1.40. View

2.
Shlaes D, Gerding D, John Jr J, Craig W, Bornstein D, Duncan R . Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997; 25(3):584-99. DOI: 10.1086/513766. View

3.
Diasio R, Bennett J, Myers C . Mode of action of 5-fluorocytosine. Biochem Pharmacol. 1978; 27(5):703-7. DOI: 10.1016/0006-2952(78)90507-5. View

4.
Joseph-Horne T, Hollomon D, Loeffler R, Kelly S . Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother. 1995; 39(7):1526-9. PMC: 162775. DOI: 10.1128/AAC.39.7.1526. View

5.
Jarvis W . Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993; 167(5):1247-51. DOI: 10.1093/infdis/167.5.1247. View